VBIV (VBI Vaccines, Inc.) יחס שווי שוק לשווי בספרים

The VBI Vaccines Inc. (VBIV) business model is based on the commercialization of PreHevbrio and advancements in immunotherapy. This chart of market and book valuation metrics demonstrates current volatility, where -0.32 describes the current status of the metric. Diversification through the development of cancer vaccines mitigates risks; however, management initiated asset liquidation due to bankruptcy, which completely destroyed operational stability and investor confidence.

The development of the vaccine pipeline at VBI Vaccines Inc. (VBIV) and the success of its glioblastoma therapy directly influence investor market expectations. These hopes are reflected in the calculation of the market-to-book value ratio. This metric measures market capitalization relative to a single unit of equity. High values signal a premium valuation of future successes but carry impairment risks. By analyzing changes in the ratio of market value to book capitalization, one can assess the degree to which the asset is overbought.